Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclic Opioid Peptides.

Michael Remesic, Yeon Sun Lee1, Victor J Hruby

  • 1Department of Chemistry and Biochemistry, 1306 E. University, P.O. Box 210041, University of Arizona, Tucson, Arizona 85721, USA. yeon@email.arizona.edu.

Current Medicinal Chemistry
|April 28, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvements in a patient with upper limb double crush syndrome through integrative Korean medicine treatment: A case report.

Medicine·2025
Same author

Design, Structure-Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists.

Molecules (Basel, Switzerland)·2025
Same author

The impact of multifunctional enkephalin analogs and morphine on the protein changes in crude membrane fractions isolated from the rat brain cortex and hippocampus.

Peptides·2024
Same author

Electroacupuncture for abdominal pain relief in patients with acute pancreatitis: A three-arm randomized controlled trial.

Journal of integrative medicine·2023
Same author

Ψ and χ Angle Constrains at the C-Terminus Trp Position of the Melanotropin Tetrapeptide Ac-His-d-Phe-Arg-Trp-NH<sub>2</sub> Lead to Potent and Selective Agonists at hMC1R and hMC4R.

Journal of medicinal chemistry·2023
Same author

Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Biomolecules·2022
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026
See all related articles

Cyclic peptides offer improved pain relief by enhancing opioid receptor targeting. This review explores cyclic and polycyclic peptides for better therapeutic outcomes and bioavailability.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Neuroscience

Background:

  • Opioid receptors are key targets for pain management.
  • Endogenous opioid peptides face challenges like poor blood-brain barrier penetration and degradation.
  • Cyclization of peptides offers a strategy to improve therapeutic properties.

Purpose of the Study:

  • To review the design of opioid receptor ligands.
  • To highlight the advantages of cyclic peptides over linear ones.
  • To explore the potential of polycyclic peptides for pain treatment.

Main Methods:

  • Review of structure-activity relationship studies.
  • Analysis of various peptide scaffolds and cyclization strategies.
  • Discussion of approaches to enhance bioavailability.

Related Experiment Videos

Main Results:

  • Cyclic peptides demonstrate enhanced metabolic stability, reduced toxicity, and improved bioavailability.
  • Structure-activity relationship studies have identified promising cyclic opioid ligands.
  • Polycyclic peptide scaffolds represent an underexplored area for opioid ligand development.

Conclusions:

  • Cyclization is a powerful strategy to optimize opioid peptide therapeutics.
  • Further research into polycyclic peptides could yield novel pain treatments.
  • Enhanced bioavailability and receptor selectivity are key benefits of peptide modification.